Page last updated: 2024-09-04

vatalanib and Experimental Mammary Neoplasms

vatalanib has been researched along with Experimental Mammary Neoplasms in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Baum, O; Djonov, V; Gruber, G; Hlushchuk, R; Pruschy, M; Riesterer, O; Wood, J1
A'Hern, R; Banerjee, S; Detre, S; Dowsett, M; Evans, DB; Littlewood-Evans, AJ; Martin, LA1
Brasch, RC; Carter, WO; Floyd, E; Fu, Y; Novikov, V; Preda, A; Roberts, TP; Shames, DM; Turetschek, K; Wood, JM1

Trials

1 trial(s) available for vatalanib and Experimental Mammary Neoplasms

ArticleYear
MRI monitoring of tumor response to a novel VEGF tyrosine kinase inhibitor in an experimental breast cancer model.
    Academic radiology, 2002, Volume: 9 Suppl 2

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Contrast Media; Dextrans; Endothelial Growth Factors; Female; Ferrosoferric Oxide; Gadolinium DTPA; Intercellular Signaling Peptides and Proteins; Iron; Lymphokines; Macromolecular Substances; Magnetic Resonance Imaging; Magnetite Nanoparticles; Mammary Neoplasms, Experimental; Mice; Oxides; Phthalazines; Pyridines; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2002

Other Studies

2 other study(ies) available for vatalanib and Experimental Mammary Neoplasms

ArticleYear
Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation.
    The American journal of pathology, 2008, Volume: 173, Issue:4

    Topics: Actins; Animals; Antineoplastic Agents; Cell Proliferation; Immunohistochemistry; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Necrosis; Neovascularization, Pathologic; Phthalazines; Platelet Endothelial Cell Adhesion Molecule-1; Pyridines; Radiation, Ionizing; Time Factors; Tissue Survival; Up-Regulation; Xenograft Model Antitumor Assays

2008
Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Aug-15, Volume: 16, Issue:16

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Aromatase; Aromatase Inhibitors; Cell Line, Tumor; Cell Proliferation; Female; Humans; Immunohistochemistry; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neovascularization, Pathologic; Nitriles; Phthalazines; Pyridines; Receptors, Estrogen; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Triazoles; Xenograft Model Antitumor Assays

2010